✂ Fed’s first rate cut since 2020: Use our free Stock Screener to find new opportunities fastExplore for FREE

Henry Schein (HSIC) Tops Q2 Earnings And Revenues Estimate

Published 08/08/2017, 08:46 AM
Updated 07/09/2023, 06:31 AM
HSIC
-

Headquartered in Melville, NY, Henry Schein Inc. (NASDAQ:HSIC) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.

Currently, Henry Schein has a Zacks Rank #2 (Buy) but that could change following its second quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)We have highlighted some of the key details from the just-released announcement below:

Earnings: The Zacks Consensus Estimate remained steady at $1.73 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.75 beat this estimate by a couple of cents.

Revenues: Henry Schein posted revenues of $3.05 billion, ahead of the Zacks Consensus Estimate for revenues of $3.04 billion.

Key Stats: Revenues in the second quarter derived from Henry Schein’s Dental segment grew 8.4% year over year to $1.48 billion, while Animal Health segment recorded sales of $891.3 million, up 4.4% compared with the prior-year quarter. Revenues from Medical segment increased 6.1% year over year to $571.4 million, while sales from Technology and Value-added services segment grew 1.4% to $108.5 million.

Henry Schein, Inc. Price and EPS Surprise

Henry Schein, Inc. Price and EPS Surprise | Henry Schein, Inc. Quote

Major Factors: Per management, its four global segments gained solid market share during the quarter and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions. The company reaffirmed adjusted EPS guidance for 2017.

Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.

Check back later for our full write up on this Henry Schein earnings report later!

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>



Henry Schein, Inc. (HSIC): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.